by NMS Group | Dec 1, 2020 | 2020, News
Nerviano, 01.12.2020 Nerviano Medical Science Srl, the NMS Group subsidiary specialized in research and development of innovative oncological drugs, today announced the recent approval of a phase I clinical study for its PARP inhibitor (NMS-03305293) by China National...
by NMS Group | Nov 30, 2020 | 2020, News
Nerviano, 30.11.2020 dMed Company (Shanghai) Ltd. congratulated the recent approval of a PARP inhibitor (NMS-03305293 capsules) of its collaborator NMS Group, an Italian oncology drug discovery and development company, by the National Medical Products Administration...
by NMS Group | Oct 2, 2020 | 2020, News
Nerviano, 02.10.2020 NMS Group announces today that its board of directors has accepted the resignation of Ying Shao as CEO, effective October 1, 2020. The Board has contextually appointed as CEO Dr. Nanding Zhao. Dr. Nanding Zhao, PhD and MBA, is an executive leader...
by NMS Group | Aug 3, 2020 | 2020, News
Basel, 03.08.2020 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek® (entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid...
by NMS Group | Jul 8, 2020 | 2020, News
Calif, 08.07.2020 Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and has applied to the Ministry of Health, Labour and Welfare (MHLW) to expand the use of the Oncomine Dx...
by NMS Group | Jun 25, 2020 | 2020, News
25.06.2020 Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF). As a histology independent treatment, entrectinib targets all solid...
Welcome and Check out our new motion picture!
Recent Comments